Utility of Combinations of Biomarkers, Cognitive Markers, and Risk Factors to Predict Conversion From Mild Cognitive Impairment to Alzheimer Disease in Patients in the Alzheimer's Disease Neuroimaging Initiative

Abstract

Cognitive markers at baseline were more robust predictors of conversion than most biomarkers. Longitudinal analyses suggested that conversion appeared to be driven less by changes in the neurobiologic trajectory of the disease than by a sharp decline in functional ability and, to a lesser extent, by declines in executive function.

Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study

“…Including the clinical parameters in the gene expression model only marginally improved the diagnostic performance by increasing the prediction accuracy from 74% to 75%. This is in contrast to that observed by Gomar et al [60]. They obtained a prediction accuracy of 71% using cognitive markers only and concluded these to be generally stronger predictors than investigated biomarkers including brain volume, CSF biomarkers, and APOE genotype.…”

Mapping the Effect of the Apolipoprotein E Genotype on 4-Year Atrophy Rates in an Alzheimer Disease–related Brain Network

“…The goal of this study was to examine genotype effects on MR imaging changes over time. We did not extract longitudinal cognitive or clinical conversion data, since other published data from this cohort have already documented the effect of APOE on cognitive changes and conversion rates (17,18).…”

“…The cells were collected in plastic tubes (10 mL) coated with ethylenediaminetetraacetic acid and sent at room temperature via overnight delivery to the University of Pennsylvania baseline Mini-Mental State Examination (MMSE) score; APOE genotyping results; baseline 1.5-T MR imaging data, which were analyzed to derive cortical thickness and subcortical volume data for the ADNI by using FreeSurfer software (version 4.4); and a minimum of two other follow-up time points (6,12,18,24,36, or 48 months from baseline) with MR imaging data that had been analyzed by using FreeSurfer. All data from MR imaging examinations that were not deemed a "full pass" by ADNI qualitycontrol evaluators were excluded (15).…”

Voices from the field: Expert reflections on mild cognitive impairment

“…see Brown, Devanand, Liu, & Caccappolo, 2011;Darby, Maruff, Collie, & McStephen, 2002;Lenehan, Klekociuk, & Summers, 2012;Stephan, Matthews, McKeith, Bond, & Brayne, 2007) and the ability of certain variables in predicting outcome in MCI (e.g. see DeCarli et al, 2004;Gomar et al, 2011;Kantarci et al, 2009). Others who take a more critical view have argued that MCI is not a clinically useful construct and that it should not be a formally recognized diagnosis (Visser & Brodaty, 2006;Whitehouse & Moody, 2006).…”